JP6854710B2 - Injectable solution formulation containing pemetrexed - Google Patents
Injectable solution formulation containing pemetrexed Download PDFInfo
- Publication number
- JP6854710B2 JP6854710B2 JP2017116374A JP2017116374A JP6854710B2 JP 6854710 B2 JP6854710 B2 JP 6854710B2 JP 2017116374 A JP2017116374 A JP 2017116374A JP 2017116374 A JP2017116374 A JP 2017116374A JP 6854710 B2 JP6854710 B2 JP 6854710B2
- Authority
- JP
- Japan
- Prior art keywords
- pemetrexed
- cysteine
- solution
- salt
- solution preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005079 pemetrexed Drugs 0.000 title claims description 53
- 229940102223 injectable solution Drugs 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 title claims description 24
- 238000009472 formulation Methods 0.000 title claims description 20
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 title claims 4
- 238000002360 preparation method Methods 0.000 claims description 85
- 239000000243 solution Substances 0.000 claims description 76
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 47
- 235000018417 cysteine Nutrition 0.000 claims description 47
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 35
- 239000001301 oxygen Substances 0.000 claims description 35
- 229910052760 oxygen Inorganic materials 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000007924 injection Substances 0.000 claims description 30
- 238000002347 injection Methods 0.000 claims description 30
- 239000003960 organic solvent Substances 0.000 claims description 15
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 239000011800 void material Substances 0.000 claims description 8
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 49
- 229960002433 cysteine Drugs 0.000 description 45
- 239000000126 substance Substances 0.000 description 31
- 229940090044 injection Drugs 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 13
- 229960001305 cysteine hydrochloride Drugs 0.000 description 13
- 229920001971 elastomer Polymers 0.000 description 13
- 239000000654 additive Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 10
- -1 2-amino-4-oxo-4,7-dihydro-1H-pyrrolo [2,3-d] pyrimidin-5-yl Chemical group 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000011261 inert gas Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000007872 degassing Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940009662 edetate Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 150000001944 cysteine derivatives Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 229940037001 sodium edetate Drugs 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229960003349 pemetrexed disodium Drugs 0.000 description 2
- 229940066007 pemetrexed injection Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OQVRCWUMFBNYKF-OUKQBFOZSA-N Carbazochrome sulfonate Chemical compound CN1C(Cc2cc(\N=N\C(N)=O)c(O)cc12)S(O)(=O)=O OQVRCWUMFBNYKF-OUKQBFOZSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 229940059251 calcium bromide Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000005361 soda-lime glass Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005209 triethanolammonium group Chemical class 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Description
本発明は、ペメトレキセドの安定性が保持された注射用溶液製剤に関する。 The present invention relates to a solution formulation for injection in which the stability of pemetrexed is maintained.
ペメトレキセドは、化学名Ｎ−［４−［２−（２−アミノ−４−オキソ−４，７−ジヒドロ−１Ｈ−ピロロ［２，３−ｄ］ピリミジン−５−イル）エチル］ベンゾイル］Ｌ−グルタミン酸二ナトリウム塩を有効成分とする代謝拮抗性抗悪性腫瘍剤であり、悪性胸膜中皮腫及び切除不能な進行・再発の非小細胞肺癌の治療剤として用いられている。ペメトレキセドの医薬製剤は、有効成分のペメトレキセド水和物と添加剤のＤ−マンニトールとを含む凍結乾燥粉製剤が、ペメトレキセド注射用製剤（アリムタ（ＡＬＩＭＴＡ 登録商標））として提供されている。該製剤は、投与時に生理食塩液を加えて充分に溶解し、必要量の溶解液を抜き取り、生理食塩液に混和し１００ｍＬとして用いられる。 Pemetrexed has the chemical name N- [4- [2- (2-amino-4-oxo-4,7-dihydro-1H-pyrrolo [2,3-d] pyrimidin-5-yl) ethyl] benzoyl] L- It is a metabolic antagonist antineoplastic agent containing disodium glutamate as an active ingredient, and is used as a therapeutic agent for malignant pleural mesothelioma and unresectable advanced / recurrent non-small cell lung cancer. As a pharmaceutical preparation of pemetrexed, a lyophilized powder preparation containing the active ingredient pemetrexed hydrate and the additive D-mannitol is provided as a pemetrexed injection preparation (ALIMTA (registered trademark)). At the time of administration, the preparation is sufficiently dissolved by adding a physiological saline solution, a required amount of the dissolved solution is withdrawn, mixed with the physiological saline solution, and used as 100 mL.
一般的に凍結乾燥製剤は保存安定性に優れるものの、用時に溶解工程が必要であり、完全に溶解させるため十分な混和操作が必要となる。したがって、医用現場において、煩雑な溶解工程が不要で、希釈してすぐ投与できる溶液形態のＲＴＵ（Ｒｅａｄｙ−ｔｏ−ｕｓｅ）製剤が求められている。 In general, lyophilized preparations have excellent storage stability, but they require a dissolution step at the time of use, and a sufficient mixing operation is required to completely dissolve them. Therefore, in the medical field, there is a demand for an RTU (Ready-to-use) preparation in the form of a solution that does not require a complicated dissolution step and can be diluted and immediately administered.
ペメトレキセドは溶液安定性が低い物性であることが知られており、水溶液中で主に酸化反応を伴う分解が進行する。そこで、ペメトレキセドのＲＴＵ製剤として、水溶液中での分解を抑制した水溶液製剤処方物が報告されている。例えば特許文献１は、酸素分圧が０．２％以下のペメトレキセド二ナトリウム溶液製剤を開示しており、減圧脱気、蒸留脱気、窒素バブリング、膜脱気や触媒樹脂脱気方法等により、酸素分圧を制御した溶液製剤を記載している。
一方、種々の抗酸化性添加剤を用いて、ペメトレキセドの安定性を向上させた水溶液製剤も報告されている。特許文献２は、抗酸化剤としてモノチオグリセロール、システインまたはチオグリコール酸を用いたペメトレキセド水溶液製剤を開示している。特許文献３には、リポ酸、ジヒドロリポ酸、メチオニンまたはこれらの混合物から選択される抗酸化剤、及びラクトビオン酸、三塩基性クエン酸ナトリウムまたはこれらの混合物から選択されるキレート剤を含有するペメトレキセド溶液製剤が記載されている。特許文献４には、クエン酸及びシステインから選択される抗酸化剤を含むペメトレキセド溶液製剤が記載されている。特許文献５には、システイン、アルギニン及びプロピレングリコールを含有するペメトレキセド溶液製剤が記載されている。特許文献６には、システイン及びチオグリセリンを含有するペメトレキセド溶液製剤が記載されている．特許文献７には、アセチルシステイン及びクエン酸ナトリウムを含有するペメトレキセド溶液製剤が記載されている。
Pemetrexed is known to have low solution stability, and decomposition mainly accompanied by an oxidation reaction proceeds in an aqueous solution. Therefore, as an RTU preparation of pemetrexed, an aqueous solution preparation formulation in which decomposition in an aqueous solution is suppressed has been reported. For example, Patent Document 1 discloses a pemetrexed disodium solution preparation having an oxygen partial pressure of 0.2% or less, which is subjected to decompression degassing, distillation degassing, nitrogen bubbling, membrane degassing, catalytic resin degassing, and the like. A solution formulation in which the partial pressure of oxygen is controlled is described.
On the other hand, aqueous solution preparations in which the stability of pemetrexed is improved by using various antioxidant additives have also been reported. Patent Document 2 discloses an aqueous solution preparation of pemetrexed using monothioglycerol, cysteine or thioglycolic acid as an antioxidant. Patent Document 3 describes a pemetrexed solution containing an antioxidant selected from lipoic acid, dihydrolipoic acid, methionine or a mixture thereof, and a chelating agent selected from lactobionic acid, sodium tribasic citrate or a mixture thereof. The formulation is listed. Patent Document 4 describes a pemetrexed solution preparation containing an antioxidant selected from citric acid and cysteine. Patent Document 5 describes a pemetrexed solution preparation containing cysteine, arginine and propylene glycol. Patent Document 6 describes a pemetrexed solution preparation containing cysteine and thioglycerin. Patent Document 7 describes a pemetrexed solution preparation containing acetylcysteine and sodium citrate.
本発明が解決しようとする課題は、ペメトレキセドの類縁物質生成抑制効果のあるシステインを使用し、長期保存においても、類縁物質の生成を抑制すると共に不溶性異物の生成が抑制されたペメトレキセドを含む注射用溶液製剤を提供することにある。特には、ペメトレキセドのシステインを用いた溶液形態のＲＴＵ製剤として、有機溶剤等の不溶性類縁物質可溶化剤を用いなくても良い単純な組成のペメトレキセド溶液製剤を提供することを課題とする。 The problem to be solved by the present invention is to use cysteine, which has an effect of suppressing the production of pemetrexed related substances, and for injection containing pemetrexed, which suppresses the production of related substances and suppresses the production of insoluble foreign substances even in long-term storage. The purpose is to provide a solution formulation. In particular, it is an object of the present invention to provide a pemetrexed solution preparation having a simple composition that does not require the use of an insoluble related substance solubilizer such as an organic solvent as a solution-form RTU preparation using cysteine of pemetrexed.
本発明は、ペメトレキセド有効成分とする注射用溶液製剤において、システイン又はその塩を０．３ｍｇ／ｍＬ〜２ｍｇ／ｍＬで用いてｐＨを９．０以上に調整することで、有機溶剤を用いなくても、有効成分であるペメトレキセドの分解を抑制するとともに、不溶性異物の生成を抑制できることを見出したことに基づく。以下の［１］〜［４］に記載の発明を要旨とする。
［１］ペメトレキセド又は薬学的に許容できるその塩、システイン又はその塩を含有する注射用溶液製剤であって、前記システインの濃度が０．３ｍｇ／ｍＬ〜２ｍｇ／ｍＬであり、ｐＨが９．０以上であり、有機溶剤を含まないペメトレキセドを含有する注射用溶液製剤。
［２］密閉容器に封入され、容器内の空隙酸素濃度が１％以下である前記［１］に記載の注射用溶液製剤。
［３］ペメトレキセドの濃度が５〜５０ｍｇ／ｍＬである前記［１］又は［２］に記載の注射用溶液製剤
［４］ｐＨが９．０〜１２．０である前記［１］乃至［３］の何れか一項に記載の注射用溶液製剤
In the present invention, in an injectable solution preparation containing pemetrexed as an active ingredient, cysteine or a salt thereof is used at 0.3 mg / mL to 2 mg / mL to adjust the pH to 9.0 or more, thereby eliminating the use of an organic solvent. It is also based on the finding that it can suppress the decomposition of pemetrexed, which is an active ingredient, and the formation of insoluble foreign substances. The inventions described in the following [1] to [4] are the gist.
[1] A solution preparation for injection containing pemetrexed or a pharmaceutically acceptable salt thereof, cysteine or a salt thereof, wherein the concentration of the cysteine is 0.3 mg / mL to 2 mg / mL and the pH is 9.0. The above is the above, and the solution preparation for injection containing pemetrexed which does not contain an organic solvent.
[2] The injectable solution preparation according to the above [1], which is sealed in a closed container and has a void oxygen concentration of 1% or less in the container.
[3] The injectable solution preparation according to the above [1] or [2], wherein the concentration of pemetrexed is 5 to 50 mg / mL [4] The pH is 9.0 to 12.0, and the above [1] to [3] ]. The solution preparation for injection according to any one of the items.
本発明のペメトレキセドを含有する注射用溶液製剤は、保存条件下において、ペメトレキセドの分解物である類縁物質の生成を抑制することができ、且つ不溶性異物を抑制することができ、保存安定性に優れたペメトレキセドのＲＴＵ製剤を提供することができる。特にプロピレングリコール等の有機溶剤を用いることのない製剤処方とすることができ、ペメトレキセドの効能および安全性を長期に亘って保持することができ、安全性に優れ、投与溶液の調製が容易な製剤を提供することができる。 The injectable solution preparation containing pemetrexed of the present invention can suppress the formation of related substances which are decomposition products of pemetrexed under storage conditions, and can suppress insoluble foreign substances, and is excellent in storage stability. An RTU formulation of pemetrexed can be provided. In particular, a formulation that does not use an organic solvent such as propylene glycol can be prepared, the efficacy and safety of pemetrexed can be maintained for a long period of time, the formulation is excellent in safety, and the administration solution can be easily prepared. Can be provided.
本発明は、ペメトレキセドを有効成分とする注射用溶液製剤において、有機溶剤を含まず、システイン又はその塩を０．３〜２ｍｇ／ｍＬになるように用い、ｐＨを９．０〜１１．０としたペメトレキセドを含有する注射用溶液製剤である。以下にその詳細をについて説明する。 In the present invention, in an injectable solution preparation containing pemetrexed as an active ingredient, cysteine or a salt thereof is used so as to be 0.3 to 2 mg / mL without containing an organic solvent, and the pH is set to 9.0 to 11.0. It is a solution preparation for injection containing pemetrexed. The details will be described below.
本発明におけるペメトレキセドは、代謝拮抗性抗腫瘍剤の有効成分として用いられている、化学名でＮ−［４−［２−（２−アミノ−４−オキソ−４，７−ジヒドロ−１Ｈ−ピロロ［２，３−ｄ］ピリミジン−５−イル）エチル］ベンゾイル］Ｌ−グルタミン酸であり、その薬学的に許容できるその塩である。前記薬学的に許容できる塩とは、ナトリウム塩、カリウム塩、リチウム塩、カルシウム塩、マグネシウム塩、アンモニウム塩、トリメチルアンモニウム塩、トリエチルアンモニウム塩、モノエタノールアンモニウム塩、トリエタノールアンモニウム塩、ピリジニウム塩、置換ピリジニウム塩などの医薬的に許容し得るアルカリ金属塩、アルカリ土類金属塩、アンモニウム塩および置換アンモニウム塩などが挙げられる。ナトリウム塩を用いることが好ましく、２ナトリウム塩であることが好ましい。すなわち、本発明において、ペメトレキセド２ナトリウム塩を用いることが好ましい。前記ペメトレキセド又は薬学的に許容できるその塩は、無水物又は水和物や溶媒和物であっても良い。水和物としては２．５水和物や７水和物が知られており、特に限定なく用いることができる。 Pemetrexed in the present invention is used as an active ingredient of an antimetabolite antitumor agent, and has a chemical name of N- [4- [2- (2-amino-4-oxo-4,7-dihydro-1H-pyrrolo). [2,3-d] pyrimidin-5-yl) ethyl] benzoyl] L-glutamic acid, a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salts include sodium salt, potassium salt, lithium salt, calcium salt, magnesium salt, ammonium salt, trimethylammonium salt, triethylammonium salt, monoethanolammonium salt, triethanolammonium salt, pyridinium salt, and substitution. Pharmaceutically acceptable alkali metal salts such as pyridinium salts, alkaline earth metal salts, ammonium salts and substituted ammonium salts and the like can be mentioned. It is preferable to use a sodium salt, and a disodium salt is preferable. That is, in the present invention, it is preferable to use the pemetrexed disodium salt. The pemetrexed or its pharmaceutically acceptable salt may be anhydrous, hydrate or solvate. As the hydrate, 2.5 hydrate and heptahydrate are known, and can be used without particular limitation.
本発明は、システイン又はシステイン塩を用いる。該システイン塩は、ナトリウム塩、カリウム塩、リチウム塩、アンモニウム塩、アミン塩、ピリジニウム塩等の薬学的に許容できる塩で用いることができる。本発明の溶液製剤を調製する場合ためには、システイン又はシステイン塩酸塩を用いることが好ましい。しかしながら、本発明に係る溶液製剤はｐＨ９．０以上であることから、当該溶液製剤中においては、その設定ｐＨに調整するためのｐＨ調整剤との塩形態であるといえる。 The present invention uses cysteine or a cysteine salt. The cysteine salt can be used as a pharmaceutically acceptable salt such as a sodium salt, a potassium salt, a lithium salt, an ammonium salt, an amine salt and a pyridinium salt. When preparing the solution preparation of the present invention, it is preferable to use cysteine or cysteine hydrochloride. However, since the solution preparation according to the present invention has a pH of 9.0 or higher, it can be said that the solution preparation is in the form of a salt with a pH adjuster for adjusting to the set pH.
前記システインの濃度は、０．３ｍｇ／ｍＬ以上で用いることが好ましく、上限は３ｍｇ／ｍＬ以下で用いることが好ましい。システインの濃度とは、システイン又はその塩の添加量から、システイン換算とした質量濃度を示す。システイン濃度が０．３ｍｇ／ｍＬ未満である場合、保存期間中における十分な類縁物質生成抑制効果が得られない可能性がある。一方、システイン濃度が３ｍｇ／ｍＬより多い場合、保存期間中における不溶性異物の生成が起こり得る可能性がある。好ましくは、システイン換算濃度として０．３ｍｇ／ｍＬ以上で２ｍｇ／ｍＬ以下の濃度である。さらに好ましくは、０．５ｍｇ／ｍＬ以上で２．０ｍｇ／ｍＬ以下の濃度である。 The concentration of the cysteine is preferably 0.3 mg / mL or more, and the upper limit is preferably 3 mg / mL or less. The concentration of cysteine indicates the mass concentration in terms of cysteine from the amount of cysteine or a salt thereof added. If the cysteine concentration is less than 0.3 mg / mL, it may not be possible to obtain a sufficient effect of suppressing the production of related substances during the storage period. On the other hand, if the cysteine concentration is higher than 3 mg / mL, the formation of insoluble foreign matter may occur during the storage period. Preferably, the cysteine equivalent concentration is 0.3 mg / mL or more and 2 mg / mL or less. More preferably, the concentration is 0.5 mg / mL or more and 2.0 mg / mL or less.
ペメトレキセド注射用溶液製剤中の類縁物質を抑制するための抗酸化剤として、システイン又はその塩を用いることは広く知られている。しかしながら、本発明者らの検討において、該溶液製剤の長期保存中に、システイン又はその塩が水に不溶な酸化体が生成し、これが不溶性異物として出現してしまうことが見出された。従来の製剤例は、システイン又はその塩を抗酸化剤として用いる場合には、アスコルビン酸やチオグリセリン等の他の抗酸化剤を併用する製剤例、抗酸化剤協力剤としてＥＤＴＡ等のキレート剤やクエン酸、酒石酸等の有機酸類を共存させる製剤例や、更にプロピレングリコール等の有機溶剤を添加した溶液製剤である。すなわち、抗酸化剤としてシステイン又はその塩を用いる場合、システイン又はその塩の使用量を制限するために他の添加剤と併用することとなり、多くの製剤添加剤や溶剤を含む複雑な製剤処方とする必要があった。
しかしながら、製剤用添加剤であっても人体に対して望ましくない副作用を示す場合がある。例えば、キレート剤であるＥＤＴＡは、静脈内投与による炎症作用やアレルギー作用の可能性等の副作用が知られている。したがって、有機溶剤やキレート剤等の添加剤を複数種類で使用することは控えることが望ましい。注射用溶液製剤としては、有効成分とその溶媒である水以外の添加剤は極力少ないものとして、単純な製剤処方の溶液製剤とすることが望ましいといえる。
It is widely known to use cysteine or a salt thereof as an antioxidant for suppressing related substances in pemetrexed injectable solution preparations. However, in the studies by the present inventors, it was found that during long-term storage of the solution preparation, an oxidant in which cysteine or a salt thereof is insoluble in water is formed, and this appears as an insoluble foreign substance. Conventional preparation examples include, when cysteine or a salt thereof is used as an antioxidant, a preparation example in which another antioxidant such as ascorbic acid or thioglycerin is used in combination, a chelating agent such as EDTA as an antioxidant cooperating agent, or Examples of preparations in which organic acids such as citric acid and tartaric acid coexist, and solution preparations in which an organic solvent such as propylene glycol is further added. That is, when cysteine or a salt thereof is used as an antioxidant, it is used in combination with other additives in order to limit the amount of cysteine or a salt thereof, and it is necessary to use a complicated formulation containing many formulation additives and solvents. I had to do it.
However, even pharmaceutical additives may show unwanted side effects on the human body. For example, EDTA, which is a chelating agent, is known to have side effects such as inflammatory action and possible allergic action due to intravenous administration. Therefore, it is desirable to refrain from using multiple types of additives such as organic solvents and chelating agents. As a solution preparation for injection, it is desirable to make a solution preparation having a simple preparation formulation, assuming that the amount of additives other than the active ingredient and its solvent, water, is as small as possible.
本発明は、ペメトレキセド及びシステイン又はその塩を含有する溶液製剤であって、そのｐＨを９．０以上とすることで、ペメトレキセド由来の類縁物質生成を抑制すると共に、システインに由来すると考えられる不溶性異物の生成を抑制できる。したがって、可溶化剤等の有機溶剤や、キレート剤等を用いることなしに、長期保存期間中も安定性を維持した注射用溶液製剤を見出した。
本発明の注射用溶液製剤のｐＨは９．０以上であり、好ましくはｐＨが９．０以上で１２．０以下の注射用溶液製剤である。より好ましくは、ｐＨが９．０以上で１１．０以下の注射用溶液製剤である。更に好ましくは、ｐＨが１０．０以上で１１．０以下の注射用溶液製剤である。
当該注射用溶液製剤は、ペメトレキセド又は薬学的に許容できるその塩、システイン又はシステイン塩酸塩、並びに任意の他の添加剤を、有機溶剤を含まず、水を主体とする溶媒により溶液を調製し、これにｐＨ調整剤又は緩衝剤を用いてｐＨを９．０以上に調整することで調製することができる。
ｐＨ調整剤としては、例えば、塩酸、水酸化ナトリウム、酢酸やその塩、リン酸やその塩、クエン酸やその塩、酒石酸やその塩などがあげられる。緩衝剤としては、前記ｐＨ調整剤の酸及び塩基の組み合せを用いればよく、例えば、リン酸及びその塩、クエン酸及びその塩、酢酸及びその塩等を挙げることができる。
The present invention is a solution preparation containing pemetrexed and cysteine or a salt thereof, and by setting the pH to 9.0 or higher, the production of related substances derived from pemetrexed is suppressed, and an insoluble foreign substance considered to be derived from cysteine is suppressed. Can be suppressed. Therefore, we have found an injectable solution formulation that maintains stability even during a long-term storage period without using an organic solvent such as a solubilizer or a chelating agent.
The pH of the injectable solution preparation of the present invention is 9.0 or more, preferably 9.0 or more and 12.0 or less. More preferably, it is an injectable solution preparation having a pH of 9.0 or more and 11.0 or less. More preferably, it is an injectable solution preparation having a pH of 10.0 or more and 11.0 or less.
The injectable solution formulation is prepared by preparing a solution of pemetrexed or a pharmaceutically acceptable salt thereof, cysteine or cysteine hydrochloride, and any other additive with a solvent containing no organic solvent and mainly containing water. It can be prepared by adjusting the pH to 9.0 or more by using a pH adjuster or a buffer.
Examples of the pH adjuster include hydrochloric acid, sodium hydroxide, acetic acid and its salt, phosphoric acid and its salt, citric acid and its salt, tartaric acid and its salt and the like. As the buffering agent, a combination of the acid and the base of the pH adjusting agent may be used, and examples thereof include phosphoric acid and its salt, citric acid and its salt, acetic acid and its salt and the like.
本発明の注射用溶液製剤において、医薬品の添加物として許容される有機溶剤は含まない。医薬品の添加物として許容される有機溶剤とは、例えば、エタノール、ベンジルアルコール、ジブチルヒドロキシトルエン、ソルビタン脂肪酸エステル、ソルビタンセスキオレイン酸エステル、プロピレングリコール、ベンジルアルコール、ポリオキシエチレン硬化ヒマシ油、ポリソルベート２０、ポリソルベート８０、マクロゴール類、モノエタノールアミンなどがあげられる。すなわち、本発明の注射用溶液製剤は、水を唯一溶剤として含有する水溶液製剤である。 The injectable solution formulation of the present invention does not contain an organic solvent that is acceptable as a pharmaceutical additive. Organic solvents that are acceptable as additives for pharmaceuticals include, for example, ethanol, benzyl alcohol, dibutylhydroxytoluene, sorbitan fatty acid ester, sorbitan sesquioleate, propylene glycol, benzyl alcohol, polyoxyethylene hydrogenated castor oil, polysorbate 20, Examples thereof include polysorbate 80, macrogols, and monoethanolamine. That is, the solution preparation for injection of the present invention is an aqueous solution preparation containing water as the only solvent.
本発明の注射用溶液製剤において、システイン又はシステイン塩以外の他の添加剤を、ペメトレキセドの安定性を維持する範囲において用いても良い。該他の添加剤としては、通常の医薬製剤に用いられる抗酸化剤、等張化剤、キレート剤、安定化剤等を添加しても良い。
抗酸化剤としては、例えば、アスコルビン酸、亜硫酸ナトリウム、亜硫酸水素ナトリウム、ピロ亜硫酸ナトリウム、クエン酸、チオグリコール酸ナトリウム、αチオグリセリン、エデト酸ナトリウム、メチオニン、アセチルシステインなどがあげられる。
キレート剤としては、例えば、エデト酸ナトリウム（ＥＤＴＡ）があげられる。
等張化剤としては、塩化ナトリウム、塩化カルシウム、塩化マグネシウム、グリセリン、果糖、キシリトール、ソルビトール、トレハロース、ニコチンアミド、ブドウ糖、精製白糖、マンニトールなどがあげられる。
安定化剤としては、例えば、アセチルトリプトファン、アラニン、アルギニンやその塩、アルブミン、安息香酸やその塩、イノシトール、ヒスチジンやその塩、果糖、カルジアミドナトリウム、カルバゾクロムスルホン酸ナトリウム、炭酸ナトリウム、キシリトール、グリシン、グルタミン酸やその塩、クレアチニン、リン酸二水素ナトリウム、コンドロイチン硫酸ナトリウム、ジエチレントリアミン五酢酸、シスチン、臭化カルシウム、ゼラチン、ソルビトール、炭酸水素ナトリウム、チオシアン酸カリウム、デキストラン、糖酸カルシウム、ナトリウムホルムアルデヒドスルホシレート、ニコチン酸アミド、乳酸、乳糖、尿素、パラオキシ安息香酸プロピル、パラオキシ安息香酸メチル、氷酢酸、ベンザルコニウム、ベンゼトニウム、マルトース、ピロリン酸ナトリウム、マレイン酸、リン酸やその塩、メグルミン、メタスルホ安息香酸ナトリウム、リジン塩酸塩、硫酸マグネシウムなどがあげられる。
但し、これらの添加剤は必須としない任意成分である。より好ましくは、本発明の溶液製剤はキレート剤であるエデト酸ナトリウム（ＥＤＴＡ）を含まない製剤であることが好ましい。更に、本発明の溶液製剤は、他の抗酸化剤を含有せずに、システインを唯一の抗酸化剤として用いることが好ましい。
In the injectable solution preparation of the present invention, additives other than cysteine or cysteine salt may be used as long as the stability of pemetrexed is maintained. As the other additives, antioxidants, isotonic agents, chelating agents, stabilizers and the like used in ordinary pharmaceutical preparations may be added.
Examples of the antioxidant include ascorbic acid, sodium sulfite, sodium hydrogen sulfite, sodium pyrosulfite, citric acid, sodium thioglycolate, α-thioglycerin, sodium edetate, methionine, acetylcysteine and the like.
Examples of the chelating agent include sodium edetate (EDTA).
Examples of the tonicity agent include sodium chloride, calcium chloride, magnesium chloride, glycerin, fructose, xylitol, sorbitol, trehalose, nicotine amide, glucose, purified sucrose, mannitol and the like.
Stabilizers include, for example, acetyltryptophan, alanine, arginine and its salts, albumin, benzoic acid and its salts, inositol, histidine and its salts, fructose, sodium cardiamide, sodium carbazochrome sulfonate, sodium carbonate, xylitol, glycine. , Glutamic acid and its salts, creatinine, sodium dihydrogen phosphate, sodium chondroitin sulfate, diethylenetriamine pentaacetic acid, cystine, calcium bromide, gelatin, sorbitol, sodium hydrogencarbonate, potassium thiosocyanate, dextran, calcium saccharide, sodium formaldehyde sulfosi Rate, nicotinic acid amide, lactic acid, lactose, urea, propyl paraoxybenzoate, methyl paraoxybenzoate, glacial acetic acid, benzalconium, benzethonium, maltose, sodium pyrophosphate, maleic acid, phosphate and its salts, meglumin, metasulfobenzoic acid Examples include sodium acid acid, lysine hydrochloride, magnesium sulfate and the like.
However, these additives are optional components that are not essential. More preferably, the solution preparation of the present invention is a preparation that does not contain sodium edetate (EDTA), which is a chelating agent. Furthermore, it is preferable that the solution preparation of the present invention does not contain other antioxidants and uses cysteine as the only antioxidant.
本発明の注射用溶液製剤におけるペメトレキセドの濃度は５ｍｇ／ｍＬ以上で５０ｍｇ／ｍＬ以下に設定することが好ましい。より好ましくは、ペメトレキセド濃度として１０ｍｇ／ｍＬ以上で４０ｍｇ／ｍＬ以下である。 The concentration of pemetrexed in the injectable solution preparation of the present invention is preferably set to 5 mg / mL or more and 50 mg / mL or less. More preferably, the pemetrexed concentration is 10 mg / mL or more and 40 mg / mL or less.
本発明の注射用溶液製剤は、バイアル状容器に無菌的に充填され、気密性のゴム栓で封止した密封充填製剤として調製される。
使用される容器としては、ゴム栓等で密封可能であれば、バイアル状、シリンジ状等の形状は特に限定されないが、バイアル状の形状が好ましい。容器の材質としては、例えばソーダライムガラス製、ホウケイ酸ガラス製、環状ポリオレフィンポリマー製、環状ポリオレフィンコポリマー製があげられる。また当該容器は、安定性の向上やガラス成分の溶出抑制等の目的に応じて表面処理された容器を用いることができる。表面処理されたバイアルの例として、シリコートバイアル（不二硝子（株）製）、ＶＩＳＴバイアル（大和特殊硝子（株）製）、ＶＩＡＬＥＸ（ニプロ（株）製）、ｔｙｐｅ１ ｐｌｕｓ（ＳＣＨＯＴＴ（株）製）などが挙げられる。
この容器を用いて、本発明の方法で脱酸素処理を行い、気密性のゴム栓で封止することにより、高度に脱酸素された注射用溶液製剤を調製することができる。ゴム栓の材質としては、ブチルゴム製のもの、さらにフッ素樹脂によりラミネートされたブチルゴム製のゴム栓を使用するのが好ましい。
これらの封止可能な容器は、容器及びゴム栓共に適当な方法により滅菌処理を施した包材であることが好ましい。
The solution preparation for injection of the present invention is prepared as a sealed filling preparation that is aseptically filled in a vial-shaped container and sealed with an airtight rubber stopper.
The container to be used is not particularly limited in shape such as a vial or a syringe as long as it can be sealed with a rubber stopper or the like, but a vial shape is preferable. Examples of the material of the container include soda lime glass, borosilicate glass, cyclic polyolefin polymer, and cyclic polyolefin copolymer. Further, as the container, a container whose surface has been surface-treated can be used for the purpose of improving stability and suppressing elution of glass components. Examples of surface-treated vials are Siricoat vials (manufactured by Fuji Glass Co., Ltd.), VIST vials (manufactured by Daiwa Special Glass Co., Ltd.), VIALEX (manufactured by Nipro Co., Ltd.), type1 plus (manufactured by SCHOTT Co., Ltd.). ) And so on.
A highly deoxidized injectable solution preparation can be prepared by deoxidizing the container according to the method of the present invention and sealing it with an airtight rubber stopper. As the material of the rubber stopper, it is preferable to use a rubber stopper made of butyl rubber or a rubber stopper made of butyl rubber laminated with a fluororesin.
These sealable containers are preferably packaging materials that have been sterilized by an appropriate method for both the container and the rubber stopper.
ペメトレキセドは、主に酸化によって類縁物質を生成することが知られている。従って、本発明の注射用溶液製剤は、溶液中の溶存酸素の濃度を制御することが好ましく、このため、該製剤の容器の空隙の酸素濃度が１％以下とすることが好ましい。容器内の空隙部分の酸素濃度を制御することにより当該溶液中の溶存酸素を低減して制御することができる。より好ましくは、容器の空隙の酸素濃度が０．５％以下の注射用溶液製剤である。
溶液中の溶存酸素濃度は、酸素センサーを用いた酸素濃度測定器により測定することができる。例えば、ニードル式酸素センサーを接続した酸素濃度計（ＭｉｃｒｏｘＴＸ３、製造元：ＰｒｅＳｅｎｓ社）を用い、当該注射用溶液製剤の溶液に酸素濃度計の酸素センサーを接液させることで、本発明に係る密封状態のバイアル製剤中の溶存酸素濃度を測定することができる。
なお、本発明の注射用製剤は、バイアル充填された溶液以外の空間（ヘッドスペース）は、窒素やアルゴン等の不活性ガスが充填されていることが好ましい。溶存酸素濃度は、ヘッドスペース内の酸素分圧に影響する。溶存酸素濃度を減少させるためには、ヘッドスペース内の酸素を除去することが有効であり、窒素やアルゴン等の不活性ガスを充填しておくことが好ましい。
Pemetrexed is known to produce related substances mainly by oxidation. Therefore, in the solution preparation for injection of the present invention, it is preferable to control the concentration of dissolved oxygen in the solution, and for this reason, it is preferable that the oxygen concentration in the void of the container of the preparation is 1% or less. By controlling the oxygen concentration in the void portion in the container, the dissolved oxygen in the solution can be reduced and controlled. More preferably, it is an injectable solution preparation having an oxygen concentration of 0.5% or less in the voids of the container.
The dissolved oxygen concentration in the solution can be measured by an oxygen concentration measuring device using an oxygen sensor. For example, by using an oxygen concentration meter (MicroxTX3, manufacturer: PreSens) to which a needle-type oxygen sensor is connected and contacting the oxygen sensor of the oxygen concentration meter with the solution of the injection solution preparation, the sealed state according to the present invention. It is possible to measure the dissolved oxygen concentration in the vial preparation of.
In the injectable preparation of the present invention, it is preferable that the space (head space) other than the solution filled in the vial is filled with an inert gas such as nitrogen or argon. Dissolved oxygen concentration affects the partial pressure of oxygen in the headspace. In order to reduce the dissolved oxygen concentration, it is effective to remove oxygen in the headspace, and it is preferable to fill it with an inert gas such as nitrogen or argon.
本発明の注射用溶液製剤における溶液中の溶存酸素の濃度を制御する方法として、溶液が充填された容器内に、窒素やアルゴン等の不活性ガスを直接注入し、一定量の不活性ガスを注入した後に、容器をゴム栓等で密封する方法が挙げられる。この方法を用いることで、該製剤の容器の空隙の酸素濃度が１％以下とすることができ、注射用溶液中の酸素濃度を１．０ｐｐｍ以下に制御することが可能となる。
また、本発明に係る注射用溶液を充填した容器を密閉空間に設置し、空間内を薬液の任意の温度における蒸気圧を下回らない程度まで減圧し、その後、窒素やアルゴン等の不活性ガスを大気圧になるまで注入し、数時間静置した後、ゴム栓等で密栓する方法を用いても良い。この方法を用いることで、該製剤の容器の空隙の酸素濃度が１％以下とすることができ、溶液中の酸素濃度を１．０ｐｐｍ以下に制御することが可能となる。
As a method of controlling the concentration of dissolved oxygen in the solution in the injectable solution preparation of the present invention, an inert gas such as nitrogen or argon is directly injected into a container filled with the solution, and a certain amount of the inert gas is injected. After the injection, a method of sealing the container with a rubber stopper or the like can be mentioned. By using this method, the oxygen concentration in the voids of the container of the preparation can be set to 1% or less, and the oxygen concentration in the injection solution can be controlled to 1.0 ppm or less.
In addition, a container filled with the injection solution according to the present invention is installed in a closed space, the space is depressurized to the extent that it does not fall below the vapor pressure of the chemical solution at an arbitrary temperature, and then an inert gas such as nitrogen or argon is discharged. A method of injecting until the pressure reaches atmospheric pressure, allowing it to stand for several hours, and then sealing it with a rubber stopper or the like may be used. By using this method, the oxygen concentration in the voids of the container of the preparation can be set to 1% or less, and the oxygen concentration in the solution can be controlled to 1.0 ppm or less.
本発明の注射用溶液製剤は、室温、好ましくは冷所にて保存される。また、遮光下で保存することが好ましい。 The solution preparation for injection of the present invention is stored at room temperature, preferably in a cold place. Moreover, it is preferable to store it under shading.
本発明の注射用溶液製剤は、ペメトレキセドを治療剤とする疾病に対する医薬品として使用することができる。 The injectable solution preparation of the present invention can be used as a drug for diseases using pemetrexed as a therapeutic agent.
以下に、本発明を実施例により更に説明する。ただし、本発明がこれらの実施例に限定されるものではない。
［実施例１］
システイン塩酸塩水和物１０．９ｍｇ（システインに換算して７．５ｍｇ）及びペメトレキセド２ナトリウム塩２．５水和物７５５ｍｇ（ペメトレキセドに換算して６２５ｍｇ）を適量の注射用水に溶かし、適量の塩酸溶液および適量の水酸化ナトリウム溶液でｐＨ９．０に調整し、注射用水を加えて全量を２５ｍＬとした。
この溶液を、孔径０．２２μｍのメンブランフィルターを用いて無菌ろ過を行い、バイアルにろ過した液を４ｍＬ充填し、バイアルの空隙部分に窒素を注入し、ゴム栓で打栓した。その後、アルミキャップにて巻締めを行い、実施例１の注射用溶液製剤を調製した。
Hereinafter, the present invention will be further described with reference to Examples. However, the present invention is not limited to these examples.
[Example 1]
Dissolve 10.9 mg of cysteine hydrochloride hydrate (7.5 mg in terms of cysteine) and 755 mg of pemetrexed disodium salt 2.5 hydrate (625 mg in terms of pemetrexed) in an appropriate amount of water for injection, and dissolve in an appropriate amount of hydrochloric acid solution. The pH was adjusted to 9.0 with an appropriate amount of sodium hydroxide solution, and water for injection was added to make the total volume 25 mL.
This solution was aseptically filtered using a membrane filter having a pore size of 0.22 μm, the vial was filled with 4 mL of the filtered solution, nitrogen was injected into the void portion of the vial, and the vial was stoppered with a rubber stopper. Then, it was wrapped with an aluminum cap to prepare a solution preparation for injection of Example 1.
［実施例２］
前記実施例１に記載の操作において、ｐＨを１０．０とした以外は、実施例１と同様の操作を行い実施例２の注射用溶液製剤を調製した。
[Example 2]
In the operation described in Example 1, the same operation as in Example 1 was carried out except that the pH was set to 10.0, and the solution preparation for injection of Example 2 was prepared.
［実施例３］
前記実施例１に記載の操作において、システイン塩酸塩水和物の添加量を１８．１ｍｇ（システインに換算して１２．５ｍｇ）とした以外は、実施例１と同様の操作を行い実施例３の注射用溶液製剤を調製した。
[Example 3]
In the operation described in Example 1, the same operation as in Example 1 was performed except that the amount of cysteine hydrochloride hydrate added was 18.1 mg (12.5 mg in terms of cysteine). A solution formulation for injection was prepared.
［実施例４］
前記実施例１に記載の操作において、システイン塩酸塩水和物の添加量を１８．１ｍｇ（システインに換算して１２．５ｍｇ）とし、ｐＨを１０．０とした以外は、実施例１と同様の操作を行い実施例４の注射用溶液製剤を調製した。
[Example 4]
In the operation described in Example 1, the same as in Example 1 except that the amount of cysteine hydrochloride hydrate added was 18.1 mg (12.5 mg in terms of cysteine) and the pH was 10.0. An operation was carried out to prepare a solution preparation for injection of Example 4.
［実施例５］
前記実施例１に記載の操作において、システイン塩酸塩水和物の添加量を３２．６ｍｇ（システインに換算して２２．５ｍｇ）とした以外は、実施例１と同様の操作を行い実施例５の注射用溶液製剤を調製した。
[Example 5]
In the operation described in Example 1, the same operation as in Example 1 was performed except that the amount of cysteine hydrochloride hydrate added was 32.6 mg (22.5 mg in terms of cysteine). A solution formulation for injection was prepared.
［実施例６］
前記実施例１に記載の操作において、システイン塩酸塩水和物の添加量を３２．６ｍｇ（システインに換算して２２．５ｍｇ）とし、ｐＨを１０．０とした以外は、実施例１と同様の操作を行い実施例６の注射用溶液製剤を調製した。
[Example 6]
In the operation described in Example 1, the same as in Example 1 except that the amount of cysteine hydrochloride hydrate added was 32.6 mg (22.5 mg in terms of cysteine) and the pH was 10.0. An operation was carried out to prepare an injectable solution preparation of Example 6.
［実施例７］
前記実施例１に記載の操作において、システイン塩酸塩水和物の添加量を７２．５ｍｇ（システインに換算して５０．０ｍｇ）とした以外は、実施例１と同様の操作を行い実施例７の注射用溶液製剤を調製した。
[Example 7]
In the operation described in Example 1, the same operation as in Example 1 was performed except that the amount of cysteine hydrochloride hydrate added was 72.5 mg (50.0 mg in terms of cysteine). A solution formulation for injection was prepared.
［実施例８］
前記実施例１に記載の操作において、システイン塩酸塩水和物の添加量を７２．５ｍｇ（システインに換算して５０．０ｍｇ）とし、ｐＨを１０．０とした以外は、実施例１と同様の操作を行い実施例８の注射用溶液製剤を調製した。
[Example 8]
In the operation described in Example 1, the same as in Example 1 except that the amount of cysteine hydrochloride hydrate added was 72.5 mg (50.0 mg in terms of cysteine) and the pH was 10.0. An operation was carried out to prepare an injectable solution preparation of Example 8.
［比較例１］
ペメトレキセド２ナトリウム塩２．５水和物７５５ｍｇ（ペメトレキセドに換算して６２５ｍｇ）を適量の注射用水に溶かし、適量の塩酸溶液および適量の水酸化ナトリウム溶液でｐＨ７．５に調整し、注射用水を加えて全量を２５ｍＬとした。
この溶液を、孔径０．２２μｍのメンブランフィルターを用いて無菌ろ過を行い、バイアルにろ過した液を４ｍＬ充填し、バイアルの空隙部分に窒素を注入し、ゴム栓で打栓した。その後、アルミキャップにて巻締めを行い、比較例１の注射用溶液製剤を調製した。
[Comparative Example 1]
Dissolve 755 mg of pemetrexed disodium salt 2.5 hydrate (625 mg in terms of pemetrexed) in an appropriate amount of water for injection, adjust the pH to 7.5 with an appropriate amount of hydrochloric acid solution and an appropriate amount of sodium hydroxide solution, and add water for injection. The total volume was 25 mL.
This solution was aseptically filtered using a membrane filter having a pore size of 0.22 μm, the vial was filled with 4 mL of the filtered solution, nitrogen was injected into the void portion of the vial, and the vial was stoppered with a rubber stopper. Then, it was wrapped with an aluminum cap to prepare a solution preparation for injection of Comparative Example 1.
［比較例２］
システイン塩酸塩水和物７．３ｍｇ（システインに換算して５．０ｍｇ）及びペメトレキセド２ナトリウム塩２．５水和物１，５１０ｍｇ（ペメトレキセドに換算して１，２５０ｍｇ）を適量の注射用水に溶かし、適量の塩酸溶液および適量の水酸化ナトリウム溶液でｐＨ７．５に調整し、注射用水を加えて全量を５０ｍＬとした。
この溶液を、孔径０．２２μｍのメンブランフィルターを用いて無菌ろ過を行い、バイアルにろ過した液を４ｍＬ充填し、バイアルの空隙部分に窒素を注入し、ゴム栓で打栓した。その後、アルミキャップにて巻締めを行い、比較例１の注射用溶液製剤を調製した。
[Comparative Example 2]
Dissolve 7.3 mg of cysteine hydrochloride hydrate (5.0 mg in terms of cysteine) and 1,510 mg of pemetrexed disodium salt 2.5 hydrate (1,250 mg in terms of pemetrexed) in an appropriate amount of water for injection. The pH was adjusted to 7.5 with an appropriate amount of hydrochloric acid solution and an appropriate amount of sodium hydroxide solution, and water for injection was added to make the total volume 50 mL.
This solution was aseptically filtered using a membrane filter having a pore size of 0.22 μm, the vial was filled with 4 mL of the filtered solution, nitrogen was injected into the void portion of the vial, and the vial was stoppered with a rubber stopper. Then, it was wrapped with an aluminum cap to prepare a solution preparation for injection of Comparative Example 1.
［比較例３］
前記実施例１に記載の操作において、ｐＨを８．５とした以外は、実施例１と同様の操作を行い比較例３の注射用溶液製剤を調製した。
[Comparative Example 3]
In the operation described in Example 1, the same operation as in Example 1 was carried out except that the pH was set to 8.5, and the injectable solution preparation of Comparative Example 3 was prepared.
［比較例４］
前記実施例１に記載の操作において、システイン塩酸塩水和物の添加量を１８．１ｍｇ（システインに換算して１２．５ｍｇ）とし、ｐＨを８．５とした以外は、実施例１と同様の操作を行い比較例４の注射用溶液製剤を調製した。
[Comparative Example 4]
In the operation described in Example 1, the same as in Example 1 except that the amount of cysteine hydrochloride hydrate added was 18.1 mg (12.5 mg in terms of cysteine) and the pH was 8.5. An operation was carried out to prepare a solution preparation for injection of Comparative Example 4.
［比較例５］
前記実施例１に記載の操作において、システイン塩酸塩水和物の添加量を３２．６ｍｇ（システインに換算して２２．５ｍｇ）とし、ｐＨを８．５とした以外は、実施例１と同様の操作を行い比較例５の注射用溶液製剤を調製した。
[Comparative Example 5]
In the operation described in Example 1, the same as in Example 1 except that the amount of cysteine hydrochloride hydrate added was 32.6 mg (22.5 mg in terms of cysteine) and the pH was 8.5. An operation was carried out to prepare a solution preparation for injection of Comparative Example 5.
［比較例６］
システイン塩酸塩水和物７２．５ｍｇ（システインに換算して５０．０ｍｇ）、プロピレングルコール１，２５０ｍｇ及びペメトレキセド２ナトリウム塩２．５水和物７５５ｍｇ（ペメトレキセドに換算して６２５ｍｇ）を適量の注射用水に溶かし、適量の塩酸溶液および適量の水酸化ナトリウム溶液でｐＨ９．０に調整し、注射用水を加えて全量を２５ｍＬとした。以降の操作は、実施例１と同様の操作を行い比較例６の注射用溶液製剤を調製した。
[Comparative Example 6]
Cysteine hydrochloride hydrate 72.5 mg (50.0 mg in terms of cysteine), propylene glucol 1,250 mg and pemetrexed disodium disodium salt 2.5 hydrate 755 mg (625 mg in terms of pemetrexed) for injection. The pH was adjusted to 9.0 with an appropriate amount of hydrochloric acid solution and an appropriate amount of sodium hydroxide solution, and water for injection was added to make the total volume 25 mL. Subsequent operations were the same as in Example 1 to prepare a solution preparation for injection of Comparative Example 6.
［ペメトレキセド類縁物質の分析条件］
実施例及び比較例のペメトレキセド分解由来の類縁物質を、以下の液体クロマトグラフィー（ＨＰＬＣ）条件にて分析した。
カラム：ジーエルサイエンス社製Ｉｎｅｒｔｓｉｌ ＯＤＳ―３（内径４．６ｍｍ、長さ２５ｃｍ）
カラム温度：４０℃
移動相Ａ：リン酸塩緩衝液（ｐＨ ６．８）／アセトニトリル混液（４７：３）
移動相Ｂ：アセトニトリル
送液量：１．０ｍＬ／ｍｉｎ．
波長：２２５ｎｍ
移動相の送液：表１に示す条件で送液した。
[Analytical conditions for pemetrexed-related substances]
Related substances derived from pemetrexed degradation in Examples and Comparative Examples were analyzed under the following liquid chromatography (HPLC) conditions.
Column: GL Sciences Inertsil ODS-3 (inner diameter 4.6 mm, length 25 cm)
Column temperature: 40 ° C
Mobile phase A: Phosphate buffer (pH 6.8) / acetonitrile mixture (47: 3)
Mobile phase B: Acetonitrile liquid feed rate: 1.0 mL / min.
Wavelength: 225 nm
Mobile phase liquid feed: Liquid was fed under the conditions shown in Table 1.
［表１］
［溶存酸素の測定］
ニードル式酸素センサーを接続した酸素濃度計（ＭｉｃｒｏｘＴＸ３、製造元：ＰｒｅＳｅｎｓ社）を使用した。ニードルの先端に酸素に感度を持つ蛍光染料（酸素センサー）がコートされたファイバーがあり、実施例及び比較例の注射用溶液製剤のゴム栓にニードル式酸素センサーを刺し、バイアル中の空隙部分の酸素を測定した。
[Measurement of dissolved oxygen]
An oxygen densitometer (MicroxTX3, manufacturer: PreSens) to which a needle-type oxygen sensor was connected was used. There is a fiber coated with a fluorescent dye (oxygen sensor) that is sensitive to oxygen at the tip of the needle, and the needle type oxygen sensor is pierced into the rubber stopper of the injection solution preparation of the example and the comparative example, and the void part in the vial Oxygen was measured.
［試験例１］６０℃保存安定性試験
実施例１〜８及び比較例１〜６の注射用溶液製剤を、６０℃の条件下にて最大４週間まで保存した。各製剤について、性状（着色）、ｐＨ、ペメトレキセド由来の類縁物質を評価した。また、製剤の保存試験開始時における溶液中の溶存酸素を酸素濃度計で測定した。評価結果を表２及び表３に示す。
[Test Example 1] Stability test for storage at 60 ° C. Solution preparations for injection of Examples 1 to 8 and Comparative Examples 1 to 6 were stored under the condition of 60 ° C. for up to 4 weeks. For each preparation, properties (coloring), pH, and related substances derived from pemetrexed were evaluated. In addition, the dissolved oxygen in the solution at the start of the storage test of the preparation was measured with an oxygen concentration meter. The evaluation results are shown in Tables 2 and 3.
［試験例２］２５℃保存時における不溶性異物の評価
実施例１〜８及び比較例１〜６の注射用溶液製剤を、２５℃の条件下にて２箇月保存し、保存後の製剤中の不溶性異物の有無を目視にて評価した．評価結果を表２及び表３に示す。
[Test Example 2] Evaluation of insoluble foreign matter when stored at 25 ° C. The injectable solution preparations of Examples 1 to 8 and Comparative Examples 1 to 6 were stored for 2 months under the condition of 25 ° C. The presence or absence of insoluble foreign matter was visually evaluated. The evaluation results are shown in Tables 2 and 3.
［表２］
［表３］
表２に示した実施例の溶液製剤の保存安定性試験の結果から、システインを濃度として０．３ｍｇ／ｍＬ以上添加し、ｐＨを９．０以上とすることで、不溶性異物及び類縁物質の生成を抑制し、安定性が向上することが認められた。
一方、表３に示したように、添加剤を用いない比較例１は類縁物質が増大し、着色も認められた。また、比較例２でシステインを濃度として０．１ｍｇ／ｍＬ添加したものについては、類縁物質の抑制効果は認められなかった。比較例３、４、及び５では、システイン濃度が０．３ｍｇ／ｍＬ以上であり、類縁物質の抑制効果が認められたものの、２５℃２箇月後に不溶性異物が確認された。この不溶性異物はシステインの酸化による生成物によるものと考えられる。実施例では、不溶性異物が確認されておらず、この不溶性異物はｐＨが９．０以上であれば出現しないと考えられる。
比較例６においては、有機溶剤のプロピレングリコールを添加している。実施例７のプロピレングリコールを添加していないものと比較して、類縁物質の総量が増加していた。従って有機溶剤を添加することにより、類縁物質量が増加するものと考えられる。
以上の結果から、有機溶剤を含まず、システインを０．３ｍｇ／ｍＬ以上添加し、ｐＨを９．０以上とした処方が、不溶性異物の生成を抑制し、ペメトレキセド類縁物質を最大限抑制することが明らかとなった。
From the results of the storage stability test of the solution preparations of the examples shown in Table 2, insoluble foreign substances and related substances were produced by adding cysteine as a concentration of 0.3 mg / mL or more and setting the pH to 9.0 or more. It was found that the stability was improved.
On the other hand, as shown in Table 3, in Comparative Example 1 in which no additive was used, related substances increased and coloring was also observed. In addition, in Comparative Example 2 in which cysteine was added at a concentration of 0.1 mg / mL, no inhibitory effect on related substances was observed. In Comparative Examples 3, 4, and 5, the cysteine concentration was 0.3 mg / mL or more, and the inhibitory effect on related substances was observed, but insoluble foreign substances were confirmed after 2 months at 25 ° C. This insoluble foreign substance is considered to be a product of oxidation of cysteine. In the examples, no insoluble foreign matter has been confirmed, and it is considered that this insoluble foreign matter does not appear if the pH is 9.0 or higher.
In Comparative Example 6, propylene glycol, which is an organic solvent, is added. Compared with the case where propylene glycol was not added in Example 7, the total amount of related substances was increased. Therefore, it is considered that the amount of related substances increases by adding the organic solvent.
From the above results, a formulation that does not contain an organic solvent, adds 0.3 mg / mL or more of cysteine, and has a pH of 9.0 or more suppresses the formation of insoluble foreign substances and suppresses pemetrexed-related substances to the maximum extent. Became clear.
本発明によれば、ペメトレキセドの分解に伴う類縁物質の生成を抑制した保存安定性に優れるペメトレキセドを含む注射用溶液製剤を提供することができる。本発明の注射用溶液製剤で使用している添加剤は、人への使用実績があり、且つ使用実績量以下の量である。従って、医薬的に安全で、投与時の調製が簡便なペメトレキセド注射用溶液製剤を提供することができる。
According to the present invention, it is possible to provide an injectable solution preparation containing pemetrexed, which has excellent storage stability and suppresses the production of related substances associated with the decomposition of pemetrexed. The additive used in the injectable solution preparation of the present invention has a track record of use in humans and is in an amount equal to or less than the track record of use. Therefore, it is possible to provide a solution preparation for pemetrexed injection that is pharmaceutically safe and easy to prepare at the time of administration.
Claims (4)
The injectable solution preparation according to any one of claims 1 to 3, wherein the pH is 9.0 to 12.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017116374A JP6854710B2 (en) | 2017-06-14 | 2017-06-14 | Injectable solution formulation containing pemetrexed |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017116374A JP6854710B2 (en) | 2017-06-14 | 2017-06-14 | Injectable solution formulation containing pemetrexed |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019001733A JP2019001733A (en) | 2019-01-10 |
| JP6854710B2 true JP6854710B2 (en) | 2021-04-07 |
Family
ID=65005355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017116374A Active JP6854710B2 (en) | 2017-06-14 | 2017-06-14 | Injectable solution formulation containing pemetrexed |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6854710B2 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6094388B2 (en) * | 2013-06-07 | 2017-03-15 | ニプロ株式会社 | Injectable composition comprising pemetrexed |
| EP3040074B1 (en) * | 2013-10-03 | 2018-07-25 | Fujifilm Corporation | Injection preparation and method for producing same |
| DK3124026T3 (en) * | 2014-03-28 | 2018-10-01 | Fujifilm Corp | INJECTION PREPARATION AND METHOD OF PREPARING IT |
| WO2016024369A1 (en) * | 2014-08-13 | 2016-02-18 | テバ製薬株式会社 | Medicinal composition for treating cancer |
| US20180235969A1 (en) * | 2014-10-16 | 2018-08-23 | Synthon B.V. | Liquid pharmaceutical composition comprising pemetrexed |
-
2017
- 2017-06-14 JP JP2017116374A patent/JP6854710B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019001733A (en) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005247866A (en) | Stable medicine composition containing 4,5-epoxymorphinan derivative | |
| JP6094388B2 (en) | Injectable composition comprising pemetrexed | |
| US20170224789A1 (en) | Stable injectable composition of bivalirudin and process for its preparation | |
| JP2005002123A5 (en) | ||
| JP6501399B2 (en) | Injection solution containing pemetrexed | |
| US20100016362A1 (en) | Stabilized pharmaceutical composition containing donepezil, process of producing same and method for stabilization | |
| EP2666463A1 (en) | Stabilized liquid composition comprising pemetrexed | |
| JP2020125359A (en) | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | |
| JP2019099557A (en) | Solution preparation containing bendamustine | |
| EP3206666A2 (en) | Liquid pharmaceutical composition comprising pemetrexed | |
| JP2020090481A (en) | Solution formulation containing bendamustine | |
| WO2016024369A1 (en) | Medicinal composition for treating cancer | |
| RU2695226C2 (en) | Stabilized liquid compositions of neuromuscular blockers | |
| WO2008023807A1 (en) | Stabilized pharmaceutical composition | |
| JP6936747B2 (en) | Injectable solution formulation containing palonosetron | |
| JP6854710B2 (en) | Injectable solution formulation containing pemetrexed | |
| JP5624766B2 (en) | Argatroban formulation without alcohol | |
| JPWO2018056336A1 (en) | Pemetrexed preparation | |
| JP6120766B2 (en) | Injection solution preparation and method for producing the same | |
| JP2019094284A (en) | Injection solution formulation containing pemetrexed | |
| JP7001454B2 (en) | Pharmaceutical product containing fosaprepitant | |
| JP6352476B2 (en) | Injection solution preparation and method for producing the same | |
| JP2012031151A (en) | Gemcitabine lyophilized preparation containing nicotinamide | |
| JP7090845B2 (en) | Liquid composition containing palonosetron | |
| TW202000204A (en) | Pemetrexed sodium injection solution formulation and manufacturing method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191204 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210127 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210308 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210316 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6854710 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |